DelveInsight’s, “Bladder cancer Pipeline Insight 2023,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder cancer pipeline drug profiles, including Bladder cancer clinical trials and nonclinical stage products. It also covers the Bladder cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Bladder Cancer Emerging drugs, the Bladder Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Bladder Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Bladder Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Bladder Cancer clinical trials studies, Bladder Cancer NDA approvals (if any), and product development activities comprising the technology, Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Bladder Cancer Pipeline Report
To explore more information on the latest breakthroughs in the Bladder Cancer Pipeline treatment landscape of the report, click here @ Bladder Cancer Pipeline Outlook
Bladder Cancer Overview
Bladder cancer is a disease that usually begins in the cells that line the inside of the bladder. It typically affects people older than 70 and occurs more often in men. Bladder cancer is the fifth most common form of cancer overall and the fourth most common among men. Bladder cancer usually responds well to treatment when diagnosed early. However, people who have been successfully treated for bladder cancer should be monitored afterward.
Recent Developmental Activities in the Bladder Cancer Treatment Landscape
For further information, refer to the detailed Bladder Cancer Unmet Needs, Bladder Cancer Market Drivers, and Bladder Cancer Market Barriers, click here for Bladder Cancer Ongoing Clinical Trial Analysis
Bladder Cancer Emerging Drugs Profile
CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070 was designed to work in two important and complementary ways. First, it replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. The scientific rationale and clinical profile of CG0070 make it an ideal agent to be developed for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators.
The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of the natural killer (NK) and T cells. N-803 is a novel IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. Its mechanism of action is direct specific stimulation of CD8+ T cells and NK cells through beta gamma T-cell receptor binding (not alpha) while avoiding T-reg stimulation. N-803 has improved pharmacokinetic properties, longer persistence in lymphoid tissues and enhanced anti-tumor activity compared to native, non-complexed IL-15 in vivo. N-803 is currently being evaluated for adult patients in two clinical NMIBC trials. QUILT 2005 is investigating use of N-803 in combination with BCG for patients with BCG-naïve NMIBC; QUILT 3032 is studying N-803 in combination with BCG in patients with BCG-unresponsive NMIBC CIS and Papillary Disease. In May 2022, ImmunityBio, Inc. announced it had submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for N-803, a first-in-class IL-15 superagonist, plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without Ta or T1 disease.
UroGen is developing UGN-102 (mitomycin) for intravesical solution as a primary nonsurgical alternative to repetitive TURBT. UGN-102 is an investigational formulation that utilizes our innovative technology, RTGel™ reverse-thermal hydrogel, for the treatment of low-grade NMIBC. Instilled via standard catheters, UGN-102 is designed to dwell for a period of several hours before being excreted via normal urine flow.
Trilaciclib, an IV-administered transient CDK4/6 inhibitor, is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy to improve patient outcomes. The company is currently enrolling patients in PRESERVE 3, Phase 2, randomized, open-label study of trilaciclib administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy in patients with untreated, locally advanced or metastatic urothelial carcinoma (mUC). Myeloprotection and anti-tumor efficacy endpoints are being assessed in this study.
Bladder Cancer Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Bladder cancer. The companies which have their Bladder cancer drug candidates in the most advanced stage, i.e. phase III include, CG Oncology.
Request a sample and discover the recent advances in Bladder Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Bladder Cancer Treatment Landscape
Scope of the Bladder Cancer Pipeline Insight Report
Dive deep into rich insights for drugs for Bladder Cancer Market Drivers and Bladder Cancer Market Barriers, click here @ Bladder Cancer Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Bladder Cancer Mergers and acquisitions, Bladder Cancer Licensing Activities @ Bladder Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 09193216187Address:304 S. Jones Blvd #2432, City: Las VegasState: United StatesCountry: IndiaWebsite: https://www.delveinsight.com/